Capricor Therapeutics Completes Enrollment of Phase II

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure

LOS ANGELES, March 31, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq: CAPR ), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has completed enrollment of its first Phase II clinical trial of Cenderitide in ambulatory heart failure patients. Cenderitide is in development for the outpatient treatment of patients following an acute admission for heart failure, as well as other potential indications.

The trial completed enrollment of 14 patients. Patients received up to eight consecutive days of increasing doses of Cenderitide by continuous subcutaneous infusion using Insulet's OmniPod ® drug delivery system. The trial assessed the safety, tolerability, pharmacokinetic profile and pharmacodynamic response to increasing dose levels of open-label Cenderitide administered in a stepwise fashion, with each patient receiving the entire range of doses.

"This Phase II trial is an important step in our clinical development program aimed at treating heart failure patients on an outpatient basis," said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. "Given the enormous unmet clinical need and heart failure being responsible for over 1 million hospital admissions annually and the staggering re-admission rates for these patients, the goal of this trial is to develop the potential use of Cenderitide as a therapy for patients with clinically advanced heart failure. We believe that, if approved, Cenderitide administered via a patch pump delivery system such as the OmniPod ® drug delivery system could keep patients out of the hospital and potentially lower overall costs on the healthcare system. Cenderitide is a dual receptor natriuretic peptide and recent positive results in Novartis' PARADIGM-HF trial have shown that the mechanism of action of their ARNI (angiotensin receptor neprilysin inhibitor) can raise the level of endogenous natriuretic peptides by preventing their enzymatic breakdown in chronic heart failure patients. We look forward to reporting on top line data from this trial during the second half of 2015 and announcing further clinical development plans in the coming months."

Heart Failure

According to the American Heart Association, heart failure is the leading cause of hospitalization among adults older than 65 years of age in the United States and is responsible for over 1 million hospital admissions annually. Among those patients that have been admitted, approximately 24% are re-hospitalized within one month, and 50% are re-hospitalized within six months. Additionally, the Affordable Care Act may not allow Medicare payments for heart failure re-hospitalizations within 30 days.

About Cenderitide

Cenderitide belongs to a class of drugs called natriuretic peptides. Preclinical and clinical data have shown that the natriuretic peptide class can act on multiple disease processes that play a role in negative outcomes associated with heart failure. Cenderitide is in development for the outpatient treatment of patients following an acute admission for heart failure, as well as other potential indications. Cenderitide was designed by scientists at the Mayo Clinic to be the only dual natriuretic peptide receptor agonist. Cenderitide is currently not an approved product and is strictly for investigational purposes.

For more information on Cenderitide: http://capricor.com/product-pipeline/cenderitide-product/

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com .

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on March 16, 2015, and in our Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on March 6, 2015. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

Corporate Contact Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 Media Relations Russo Partners Christopher Hippolyte +1-646-942-5634 Tony Russo, Ph.D. +1-212-845-4251 Investor Relations: Russo Partners Robert Flamm, Ph.D. +1-212-845-4226

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 156

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

NewRiver REIT Announces Scrip Dividend Reference Price

Updated Category News Views 335

NewRiver REIT's Scrip Dividend Reference Price Announcement NewRiver REIT plc has made a significant announcement regarding the reference price for its scrip dividend option, which is tied to its interim dividend. This dividend pertains to the six-month period ending on September 30, 2024. Understanding the Scrip Dividend Option The reference price has been set at 73.41...

Continue Reading
Upcoming Shareholders' Meeting Announcement for Siguldas CMAS

Updated Category News Views 200

Important Shareholders' Meeting Information The Management Board of Joint Stock Company ‘Siguldas ciltslietu un m?ksl?g?s aps?klošanas stacija’ is excited to announce an important shareholders' meeting for the company. This meeting is a key opportunity for all shareholders to engage in discussions concerning the company's future. Meeting Details Scheduled for April...

Continue Reading
Empowering Women in Finance: Insights from Cboe Leaders

Updated Category News Views 168

Empowering Women in Finance In a recent dialogue, Cathy Clay, Executive Vice President and Global Head of Derivatives at Cboe, along with Meghan Dugan, Senior Vice President overseeing U.S. Options, and Alexandra Szakats, Vice President and Head of The Options Institute, shared their journeys and advice regarding their roles as leaders in the options industry. These women...

Continue Reading
Bird Dog Whiskey Debuts Premium Kentucky Straight Bourbon

Updated Category News Views 220

Bird Dog Whiskey Unveils Select Reserve Kentucky Straight Bourbon Bird Dog Whiskey has exciting news for bourbon enthusiasts. The brand has launched a highly anticipated addition to its lineup: the Select Reserve Kentucky Straight Bourbon Whiskey. This new offering is set to capture the hearts of loyal fans. A Smooth and Rich Bourbon Experience At 86 proof, Bird Dog...

Continue Reading
Vera Therapeutics Announced Key Stock Option Grants for New Hires

Updated Category News Views 160

Introduction to Vera Therapeutics' Inducement Awards Vera Therapeutics, Inc. (Nasdaq: VERA) has proudly announced a significant step in its commitment to fostering talent by granting inducement awards to new employees. On a recent date, the Compensation Committee approved these awards, which included stock options and restricted stock units (RSUs) to reward and attract...

Continue Reading